Sarcopenia and Frailty in Heart Failure: Is There a Biomarker Signature?

Sato, Ryosuke; Vatic, Mirela; Fonseca, Guilherme Wesley Peixoto da; Haehling, Stephan von

doi:10.1007/s11897-022-00575-w

Cited by 15 publications

(8 citation statements)

References 130 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, studies suggest that the levels of sST2 may also serve as a potential predictive biomarker for frailty in patients with HF and other critical illnesses. 45,46 However, we did not observe any association of sST2 with either physical performance parameters or overall frailty in patients with CHF. Hence, sST2 may contribute to disease severity due to its crucial role in inducing systemic inflammation but may not be a predictive biomarker of frailty in critically ill patients.…”

Section: Discussioncontrasting

confidence: 72%

Circulating H-FABP as a biomarker of frailty in patients with chronic heart failure

Ahmad,

Karim,

Khan

et al. 2023

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

Increased vulnerability to physiologic stressors, termed frailty, is a common occurrence in patients with chronic heart failure (CHF). However, the definite biomarkers to assess frailty in CHF patients are not known. Here, we assessed the frailty phenotype and its potential association with heart failure (HF) markers in CHF patients. We categorized controls ( n = 59) and CHF patients ( n = 80), the participants, into robust, pre-frail, and frail based on the cardiovascular health study (CHS) frailty index. The plasma levels of HF markers, including tumorigenicity 2 (s-ST2), galectin-3, and heart-type fatty acid binding protein (H-FABP), were measured and correlated with frailty phenotype and cardiac function. The levels of plasma s-ST2, galectin-3, and H-FABP were profoundly elevated in CHF patients. Conversely, the frailty index scores were significantly lower in ischemic and non-ischemic CHF patients versus controls. Of the assessed HF markers, only H-FABP was positively correlated ( r2 = 0.07, P = 0.02) with the frailty score in CHF patients. Collectively, these observations suggest that circulating H-FABP may serve as a biomarker of frailty in CHF patients.

show abstract

Section: Discussioncontrasting

confidence: 72%

Circulating H-FABP as a biomarker of frailty in patients with chronic heart failure

Ahmad,

Karim,

Khan

et al. 2023

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

show abstract

“…Reduced HGS as a reflection of muscle wasting in patients with HF has been involved as an important component for both sarcopenia and physical frailty, which may at least partly explain the prognostic role of HGS in these patients 37 . Pathophysiologically, during the progression of HF, reduced cardiac output and systemic congestion lead to a reduction in food intake and exercise capacity, promote inflammatory responses, increase sympathetic excitability, lead to secretion changes of muscle‐related hormone, and finally result in muscular weakness 38 . Among them, the ubiquitin–proteasome system (UPS) could be activated by systemic inflammation and oxidative stress in HF, and result in autophagy and apoptosis, ultimately leading to skeletal muscle wasting 39 .…”

Section: Discussionmentioning

confidence: 99%

Handgrip strength and the prognosis of patients with heart failure: A meta‐analysis

Wang

Zhu

et al. 2023

Clinical Cardiology

View full text Add to dashboard Cite

BackgroundReduced muscular strength is common in patients with heart failure (HF). The aim of the systematic review and meta‐analysis was to evaluate the association between handgrip strength (HGS) and prognosis of patients with HF.HypothesisReduced HGS may be a risk factor of poor prognosis of patients with HF.MethodsRelevant observational studies with longitudinal follow‐up were obtained by a comprehensive search of PubMed, Embase, Cochrane Library, and Web of Science databases. A random‐effects model was used to pool the results.ResultsFifteen studies involving 7350 patients with HF were included in the meta‐analysis. Pooled results showed that HF patients with lower HGS were associated with a higher risk of mortality during follow‐up (risk ratio [RR]: 2.00, 95% confidence interval [CI]: 1.55–2.58, p < .001; I2 = 0%). Subgroup analysis showed that the association was not significantly affected by characteristics such as study country, design, mean age of the patients, HF status (stable or advanced/acute), HF type (reduced or preserved ejection fraction), follow‐up duration, and quality score (p for subgroup difference all > 0.05). Further analysis showed that per 1 kgf decrease of HGS was associated with an 8% increased risk of mortality during follow‐up (RR: 1.08, 95% CI: 1.05–1.11, p < .001; I2 = 12%). Moreover, HF patients with lower HGS were also related to a higher risk of composite outcome of HF rehospitalization or mortality (RR: 1.67, 95% CI: 1.19–2.35, p = .003; I2 = 53%).ConclusionA low HGS may be associated with poor clinical outcomes of patients with HF.

show abstract

“…Previous studies showed that sarcopenia, which is primarily characterized by a progressive and widespread decline in skeletal muscle mass and muscle dysfunction, is common in patients with HF (about 10%) and is strongly related to the prognosis of HF ( 22 ). Also, loss of lean body mass was related to the occurrence of HF, particularly among older males ( 23 ).…”

Section: Discussionmentioning

confidence: 99%

Association between changes in predicted body composition and occurrence of heart failure: a nationwide population study

Woo,

Kim,

Lee

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundLarge population-based studies on the association between changes in body composition and the occurrence of heart failure (HF) are rare. We aimed to determine the association between changes in body composition, including the predicted body fat mass index (pBFMI), predicted appendicular skeletal muscle mass index (pASMI), and predicted lean body mass index (pLBMI), and the occurrence of HF.MethodsFor present study, 2,036,940 people who consecutively underwent national health examinations from 2010~2011 (baseline period) to 2012~2013 (follow-up period) were included. The pBFMI, pASMI, and pLBMI were indirectly investigated using validated anthropometric prediction equations from the Korean National Health and Nutrition Examination Survey cohort. The outcome was defined as at least two or more claims of HF.ResultsDuring a median of 7.59 years of follow-up, 22,172 participants (event rate, 1.09%) with HF were observed. Decreased changes in the pASMI and pLBMI were associated with the occurrence of HF among males (hazard ratio [HR] 0.966, 95% confidence interval (CI) [0.944-0.988]; HR 0.939, 95%CI [0.923-0.955], respectively) and females (HR 0.924, 95%CI [0.900-0.947]; HR 0.951, 95%CI [0.939-0.963], respectively). An increased change in the pBFMI was associated with the occurrence of HF in males (HR 1.017, 95%CI [1.001-1.034]). However, paradoxically, a change in the pBFMI was associated with the occurrence of HF in females (HR 0.925, 95%CI [0.909-0.942]).ConclusionDecreased skeletal muscle mass was related to the occurrence of HF. However, the relationship between a change in fat mass and the occurrence of HF was different and even paradoxical depending on sex.

show abstract

Sarcopenia and Frailty in Heart Failure: Is There a Biomarker Signature?

Cited by 15 publications

References 130 publications

Circulating H-FABP as a biomarker of frailty in patients with chronic heart failure

Circulating H-FABP as a biomarker of frailty in patients with chronic heart failure

Handgrip strength and the prognosis of patients with heart failure: A meta‐analysis

Association between changes in predicted body composition and occurrence of heart failure: a nationwide population study

Contact Info

Product

Resources

About